Citadel Advisors
KYMR icon

Citadel Advisors’s Kymera Therapeutics KYMR Stock Holding History

Citadel Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.84M Buy
33,500
+23,600
+238% +$2.03M ﹤0.01% 5188
2026
Q1 		$825K Sell
9,900
-3,600
-27% -$285K ﹤0.01% 8106
2025
Q4 		$1.05M Sell
13,500
-400
-3% -$27K ﹤0.01% 7289
2025
Q3 		$787K Buy
+13,900
New +$627K ﹤0.01% 8062
2025
Q2 		– Sell
-4,400
Closed -$120K – 13920
2025
Q1 		$120K Sell
4,400
-1,100
-20% -$40.1K ﹤0.01% 11205
2024
Q4 		$221K Sell
5,500
-9,700
-64% -$438K ﹤0.01% 10267
2024
Q3 		$719K Buy
15,200
+800
+6% +$35.3K ﹤0.01% 7495
2024
Q2 		$430K Buy
14,400
+4,700
+48% +$163K ﹤0.01% 8366
2024
Q1 		$390K Buy
9,700
+1,600
+20% +$57.2K ﹤0.01% 8915
2023
Q4 		$206K Buy
8,100
+4,100
+103% +$73.3K ﹤0.01% 9889
2023
Q3 		$55.6K Buy
4,000
+1,800
+82% +$36.2K ﹤0.01% 11632
2023
Q2 		$50.6K Sell
2,200
-100
-4% -$2.87K ﹤0.01% 11791
2023
Q1 		$68.1K Sell
2,300
-62,000
-96% -$2M ﹤0.01% 11778
2022
Q4 		$1.6M Buy
64,300
+49,600
+337% +$1.32M ﹤0.01% 5892
2022
Q3 		$320K Buy
+14,700
New +$387K ﹤0.01% 9432
2022
Q1 		– Sell
-3,900
Closed -$248K – 14140
2021
Q4 		$248K Sell
3,900
-4,500
-54% -$262K ﹤0.01% 11385
2021
Q3 		$493K Buy
+8,400
New +$487K ﹤0.01% 9909

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Citadel Advisors's KYMR Position: Q2 2026 in Review

Citadel Advisors reduced its Kymera Therapeutics (KYMR) stake by 5.9% in Q2 2026, selling an estimated $605K and leaving 111,555 shares worth $12.8M. The position accounts for ﹤0.01% of the portfolio, ranked #3199.

Citadel Advisors first reported a position in KYMR in Q1 2021 and has held it in 21 quarters since. The position peaked at $22.6M in Q2 2025. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Citadel Advisors held 111,555 shares of Kymera Therapeutics worth $12.8M as of Q2 2026.
  • Citadel Advisors sold 7,042 Kymera Therapeutics shares in Q2 2026, an estimated $605K.
  • Kymera Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3199 holding.
  • Citadel Advisors first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Citadel Advisors's Kymera Therapeutics position peaked at $22.6M in Q2 2025.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.